China's biopharma boom at tipping point for growth, WuXi's Li says

China

Explosive growth for China's biopharma industry spurred by the return of talent after high-profile stints at companies and universities in the U.S. will accelerate in the coming two decades, the chief of the country's top CRO tells Bloomberg.

A rush by so-called Sea Turtles--as the returnees are dubbed--to biotech centers in Shanghai spurred by tax and funding incentives from the Chinese government has been in play for several years with both informal networks and formal ones such as Silicon Valley-based Bay Helix, said WuXi AppTec CEO Ge Li, who delisted the firm from the U.S. last year in a management-led buyout for $3.3 billion.

“We’re at a tipping point in China,” Li told Bloomberg. “I personally believe that we have another 10 to 20 years of good growth ahead.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The combination of returnees and local talent is a key driver as noted by Shanghai-based ZAI Lab CEO and founder Samantha Du, which earlier this year raised a bit more than $100 million in a Series B round, led by Advantech Capital, and including OrbiMed to develop in-licensed candidates. The firm is also working with Beijing-based Tsinghua University in setting up a dedicated R&D center for novel development.

Citing figures from consultancy ChinaBio, Bloomberg said investment in China’s life sciences sector exceeded $30 billion in 2015, a jump of 70%.

- here's the story from Bloomberg

Related Articles:
China's WuXi AppTec to build $120M biologics center in Shanghai
Money and policy appear to mix well in China biopharma
China's ZAI Lab's novel push gets help with $100M-plus in Series B funding

Read more on

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.